Últimas noticias sobre Purple Biotech (NASDAQ:PPBT) Bolsa

Purple Biotech

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech Ltd

Elon Musk on Friday said that he would like former congressman from Texas Ron Paul to be on the Department of Government Efficiency, a department he intends to be part of if former President Donald Trump reclaims the White House in the <a href="https://www.benzinga.com/topic/2024-election">upcoming elections</a>.
What Happened: &#8220;Would be great to have Ron Paul as part of the Department of Government Efficiency!,&#8221; Musk wrote on social media platform X.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Would be great to have Ron Paul as part of the Department of Government Efficiency!
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1852472973728338409?ref_src=twsrc%5Etfw">November 1, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk&#8217;s comment comes on the heels of Paul expressing his willingness to help Musk cut government spending in an interview with podcaster David Gornoski. However, the former member of the U.S. House of Representatives said that he wouldn&#8217;t want an official position.
Paul has previously run twice for the Republican presidential nomination. 
Why It Matters: Musk officially endorsed Trump in July after a shooting incident at a rally in Pennsylvania. The billionaire also <a href="https://www.benzinga.com/news/24/10/41197236/elon-musk-and-trump-address-thousands-at-site-of-failed-assassination-attempt-take-aim-at-bidens-lea">attended a Trump campaign event in Pennsylvania</a> in October and termed the election a "must-win situation" for Trump.
Trump, meanwhile, has expressed his intent to set up a&nbsp;<a href="https://www.benzinga.com/government/24/09/40739165/trump-plans-to-appoint-elon-musk-to-government-efficiency-commission-if-elected-tesla-ceo-says-hell" target="_blank" rel="noreferrer noopener">government efficiency commission</a>&nbsp;led by Musk if elected President. The commission will be tasked with conducting a complete financial and performance audit of the federal government and recommending reforms, Trump said in September.
Musk has previously said that the commission will also be aimed at removing what he deems as excess regulation in a bid to kickstart key projects such as building high-speed rail in the country.
Musk is actively gathering votes for Trump both online and offline. He founded a super PAC called America PAC to which he has so far given <a href="https://www.benzinga.com/news/24/10/41417390/elon-musks-pro-trump-super-pac-to-give-1m-every-day-to-people-in-swing-states-for-signing-his-petiti">over $100 million</a> in a bid to support Trump&#8217;s presidential campaign, cementing him as a key figure in this year&#8217;s election. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41647639/teslas-chinese-rival-byd-outshines-elon-musks-ev-giant-in-quarterly-revenue-for-first-time-since-202" target="_blank" rel="noreferrer noopener">Chinese EV Behemoth BYD Tops Tesla's Revenue For First Time Since 2022 In Q3</a></li>
</ul>
Photos courtesy: Shutterstock and Gage Skidmore on Flickr

News

Politics

Elon Musk Says 'Would Be Great To Have' Former Congressman And Fed Critic Ron Paul In 'Department Of Government Efficiency' If Trump Wins

Kamala Harris&#8216;s campaign and Democratic Party officials &#8220;fully expect&#8221; a premature victory declaration by Donald Trump in the <a href="https://www.benzinga.com/topic/2024-election">upcoming election</a> and are reportedly preparing for a swift response.
What Happened: Democrats are ready&nbsp;to flood social media and&nbsp;television with calls for patience and calm during the vote-counting process, reported Reuters.
This is in response to Trump&#8217;s statement expressing his intention&nbsp;to declare victory on Election&nbsp;Day, despite warnings from election experts that the final result could take several days, especially if vote recounts are demanded in key areas.
See Also:&nbsp;<a href="https://www.benzinga.com/general/politics/24/10/41630878/djt-short-squeeze-could-push-stock-to-60-if-trump-wins-but-analysis-says-loss-could-make-shares-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">DJT Short Squeeze Could Push Stock To $60 If Trump Wins, But Analysis Says Loss Could Make Shares &#8216;Worthless&#8217;</a>
&#8220;We are sadly ready if&nbsp;he does and, if we&nbsp;know that he is actually&nbsp;manipulating the press and attempting&nbsp;to manipulate the consensus of&nbsp;the American people &#8230; we&nbsp;are prepared to respond,&#8221; Harris&nbsp;stated in a Wednesday interview with ABC.
Democratic Party and campaign officials plan to wage their initial fight against any premature Trump victory claim&nbsp;in the court of public&nbsp;opinion, demanding&nbsp;that all votes be counted&nbsp;before victories are declared.
&#8220;As soon as he (Trump) falsely declares victory, we&#8217;re ready to get up on TV and provide the truth and tap a broad network of people who can use their influence to push back,&#8221; a senior Democratic National Committee official stated in an interview.
Why It Matters: In 2020, <a href="https://www.benzinga.com/news/23/08/33545892/trump-knew-he-lost-2020-election-to-biden-says-former-ag-barr-it-would-not-come-out-very-well-for-hi">Trump declared victory</a> early the morning after Election Day, three days before networks officially called the race. Though he ultimately lost to Joe Biden, he has continued to falsely claim the election was stolen through widespread fraud.
Meanwhile, the 2024 U.S. presidential race has been <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41687739/nate-silver-says-kamala-harris-may-need-backup-plans-if-the-blue-wal-is-split-but-sees-the">described as &#8220;a near coin flip,&#8221;</a> with Trump narrowly leading Harris, said American statistician and writer&nbsp;Nate Silver on Friday.
Previously, it was reported that <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41576378/donald-trumps-election-odds-improve-to-66-after-viral-joe-rogan-podcast-and-controversial-">Trump&#8217;s election odds have improved</a> to 66% after a viral Joe Rogan podcast and a controversial Madison Square Garden rally, as per&nbsp;Polymarket odds.
However, former GOP strategist Stuart Stevens has forecasted a decisive victory for Harris, predicting her to win by an even larger margin than in 2020.
As the U.S. heads into the elections, economists warn that a <a href="https://www.benzinga.com/government/24/11/41695926/a-republican-sweep-might-be-the-most-inflationary-election-outcome-economists-warn">Republican victory could significantly</a> increase inflationary pressures, primarily from higher tariffs, a swelling budget deficit, and restricted immigration policies.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41668254/conservatives-angry-with-julia-roberts-ad-urging-women-to-vote-for-kamala-harris-nauseating?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Conservatives Angry With Julia Roberts Ad Urging Women To Vote For Kamala Harris: &#8216;Nauseating&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photos courtesy: Shutterstock

Media

Kamala Harris 'Ready' If Trump Decides To 'Falsely' Declare Victory: 'We Are Prepared To Respond'

First-time homebuyers are gaining ground in unexpected territory, with Rhode Island leading a wave of Northeastern and Midwestern states where new buyers are claiming a growing share of home sales.
According to data issued by Freddie Mac initially cited by Realtor.com, Rhode Island topped the nation with a 14.3% increase in first-time buyer market share from 2019 through 2024, despite the state&#8217;s median listing price of $569,950 sitting well above the national average of $425,000.
Don't Miss:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
</ul>
The trend extends throughout the region, with Iowa, Nebraska, Wisconsin, and Connecticut all seeing first-time buyer shares climb by more than 10% over the same period.
The shift comes as first-time buyers now account for more than half of conventional conforming mortgages nationwide, up from 20% in 2004, according to Freddie Mac&#8217;s latest market outlook report.
The surge in new buyers appears strongest in areas with moderate or slower overall sales activity. Meanwhile, popular retirement destinations like Arizona and Florida saw smaller gains in first-time buyer share, likely due to competition from older Americans moving to these regions.
Only two states bucked the trend entirely, with Louisiana and North Dakota seeing slight declines in first-time buyer share over the past five years.
See Also: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
The broader picture remains challenging for new buyers. When including cash sales and unconventional loans, first-time buyers made up just 26% of all existing home sales last month, according to the National Association of Realtors — matching historic lows seen in recent months.
<a href="https://www.benzinga.com/real-estate/24/09/40771559/average-american-cant-afford-starter-homes-20k-above-their-budget-warns-real-estate-analyst">New buyers are facing significant headwinds</a>. Entry-level home prices have grown 63% more than high-end home prices since 2000, according to Freddie Mac&#8217;s analysis. The supply crunch is equally severe, with approximately 30 renter households competing for each available home for sale, up from fewer than 10 in 2006.
&#8220;Less affordable housing is acutely felt by those seeking to buy their first homes, especially those without substantial wealth at their disposal,&#8221; Freddie Mac&#8217;s report says.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today. </a>Behind the regional shift lies a demographic wave, with Millennials and the oldest members of Generation Z becoming a force in the housing market. Data from Freddie Mac shows that young adult renters are earning more than in previous years, with three million renter households between ages 25 and 44 now earning at least $75,000 annually in inflation-adjusted terms.
However, economic headwinds are mounting for those potential buyers. The unemployment rate for renters has climbed from 5% to over 6% since 2023 while remaining stable for homeowners. It's a disparity that could impact future first-time buyer activity, as most future buyers are currently renting.
Freddie Mac is responding to the challenges. In the second quarter of this year alone, the organization financed roughly 200,000 primary home purchases, with first-time buyers accounting for 53% of the transactions. The agency has also launched a new platform to help potential buyers connect with down payment assistance programs through their lenders.
The findings come as the housing market grapples with high mortgage rates and tight inventory, creating <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39614880/now-owning-a-house-in-us-is-more-challenging-than-ever-as-affordability-drops-to-">some of the toughest conditions on record for aspiring homeowners</a>.
Read Next:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Real Estate

Realtor.com Trends Reveal Millennials Are Making Gains In Surprising States As First-Time Homebuyers Surge

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

South Bow Corp. ((TSX &amp;, NYSE:<a href="https://www.benzinga.com/stock/SOBO#NYSE">SOBO</a>) has received an unsolicited "mini-tender" offer from TRC Capital Investment Corp. (TRC Capital) to purchase up to 3 million South Bow common shares, or approximately 1.4% of South Bow's outstanding common shares, at a below-market price of C$31.95. South Bow does not endorse TRC Capital's unsolicited offer, has no affiliation with TRC Capital or its offer, and does not recommend or endorse this unsolicited mini-tender offer.
South Bow cautions shareholders that the mini-tender offer has been made at a below-market price for the South Bow common shares. TRC Capital's unsolicited offer price of C$31.95 per share represents a discount of 4.6% to the closing price of the South Bow common shares on the Toronto Stock Exchange and the New York Stock Exchange on Oct. 28, 2024, the last trading day before the mini-tender offer was commenced, and a discount of 7.4% to the closing price on Nov. 1, 2024.

Management

SOBO

South Bow Recommends Shareholders Reject TRC Capital's Below-Market "Mini-tender" Offer To Purchase Up To 3M Shares, Or ~1.4% Of South Bow's Outstanding Common Shares, At A Price Of C$31.95 Per Share

As previously announced, on September 4, 2024, APX Acquisition Corp. I (NASDAQ:&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4293294-1&amp;h=2469645923&amp;u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Fapx-acquisition-corp-i-receives-nasdaq-notice-on-late-filing-of-its-form-10-q-302023280.html%23financial-modal&amp;a=APXI">APXI</a>) (the "Company"), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5452(b)(C) (the "Rule"), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the "Notice"). The Company subsequently submitted a plan to regain compliance with the Rule (the "Compliance Plan").
On October 29, 2024, the Company received written notice from the Staff (the "November Notice"), stating that the Compliance Plan was not accepted as the Company had provided insufficient evidence to demonstrate that it can effect the Compliance Plan by its 36-month expiration date of December 6, 2024, at which time the Company's securities will be delisted from Nasdaq in accordance with IM-5101-2, irrespective of the Company's progress or lack thereof toward regaining compliance with the Rule, and that the Staff had determined to initiate procedures to delist the Company's warrants (and, as a result of the warrants' inclusion therein, the Company's units) from Nasdaq due to the Company's non-compliance.
Pursuant to the Notice, unless the Company requests a hearing to appeal this determination by November 5, 2024, the Company's warrants and units will be suspended at the opening of business on November 5, 2024, and a Form 25-NSE will be filed with the SEC, which will remove the Company's warrants and units from listing and registration on Nasdaq (the "Warrant/Unit Delisting"). The Company does not intend to request a hearing. The Warrant/Unit Delisting does not affect the listing or trading of the Company's Class A ordinary shares on the&nbsp;Nasdaq Global Market, other than those contained within the units.

APXI

APXIU

APXIW

APX Acquisition Corp. I Announces Nasdaq Delisting Notification For Warrants And Units

Four Corners Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCPT#NYSE">FCPT</a>), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties ("FCPT" or the "Company"), is pleased to announce the acquisition of a Miller's Ale House property for $3.8 million. The property is located in a strong retail corridor in Georgia and is corporate-operated under a long term, net lease with approximately 11 years of term remaining. The transaction was priced at a 7.2% cap rate on rent as of the closing date and exclusive of transaction costs.

FCPT

FCPT Announces Acquisition Of A Miller's Ale House Property For $3.8M

- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, today announced that results from a Phase 1b/2 combination trial evaluating ALX Oncology's evorpacept in combination with Jazz Pharmaceuticals' zanidatamab in HER2-positive and HER2-low metastatic breast cancer have been accepted for a poster spotlight presentation at the San Antonio Breast Cancer Symposium (SABCS), which will be held in San Antonio, Texas, from December 10-13, 2024.
The Phase 1b/2 clinical trial is a two-part, open-label, multicenter study (<a href="https://www.globenewswire.com/Tracker?data=uP7TgOHeIoBZb8tHT8b8P-5Joh1B-EVwBg4vRKoa2aqEd6K1wLigVjuzGppZ4A3Pcqq8O6QfdpsX2sB5fqmpGS9NQ7SYCSmfS3RFDCelosE=">NCT05027139</a>) that evaluated the potential of evorpacept in combination with zanidatamab as a novel treatment for patients with HER2-expressing breast cancer and other cancers. Data from this study will be summarized in the following poster spotlight presentation:

Biotech

General

ALXO

ALX Oncology Announces Results From Phase 1b/2 Trial Of Evorpacept In Combination With Zanidatamab Will Be Presented At The San Antonio Breast Cancer Symposium 2024

&nbsp;Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) today announced that data from the Phase 3 trial (EMBER-3) for imlunestrant, an oral selective estrogen receptor degrader (SERD), will be reported for the first time in a late-breaking oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4292744-1&amp;h=3267956950&amp;u=https%3A%2F%2Fsabcs.org%2F&amp;a=San+Antonio+Breast+Cancer+Symposium+(SABCS)">San Antonio Breast Cancer Symposium (SABCS)</a> taking place December 10-13 in San Antonio, TX. EMBER-3 is a study in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. The trial is evaluating imlunestrant alone or in combination with Verzenio (abemaciclib; CDK4/6 inhibitor), in patients who were pretreated with endocrine therapy, with or without a CDK4/6 inhibitor.
Lilly will also share results of a real-world analysis of risk of recurrence by nodal status and high-risk features in patients with hormone receptor positive (HR+), HER2- early breast cancer. Additional presentations from investigational mutant selective PI3Ka inhibitor assets include preclinical characterization data for LY4045004, which is expected to enter the clinic in the first half of 2025, and Phase 1a/b clinical data for a predecessor molecule, LOXO-783, which informed the development of LY4045004.

Lilly To Present Results From Phase 3 EMBER-3 Study Of Imlunestrant, An Oral SERD, And Additional Results From Its Breast Cancer Portfolio At The San Antonio Breast Cancer Symposium

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4293554-1&amp;h=3420507561&amp;u=https%3A%2F%2Fwww.centene.com%2F&amp;a=Centene+Corporation">Centene Corporation</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), a leading healthcare enterprise committed to helping people live healthier lives, announced today that its subsidiary, <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4293554-1&amp;h=1525079035&amp;u=https%3A%2F%2Fwww.buckeyehealthplan.com%2F&amp;a=Buckeye+Health+Plan">Buckeye Health Plan</a>&nbsp;(Buckeye), has been selected by the Ohio Department of Medicaid (ODM) to continue providing Medicare and Medicaid services for dually eligible individuals through a Fully Integrated Dual Eligible Special Needs Plan (FIDE SNP). FIDE SNPs fully integrate care for dually eligible beneficiaries under a single managed care organization, allowing enrollees to receive all of their medical, behavioral and long-term services and supports through one plan.

Centene's Buckeye Health Plan Awarded Contract To Serve Dual Eligible Medicare And Medicaid Members In Ohio

Macro Economic Events

Economics

STLA

Republican Nominee Donald J. Trump Says 'Tell Stellantis If They Plan On Moving, We're Going To Charge Them A 100% Tariff On Every Car'

Contracts

GRYP

Gryphon Digital Mining & Unit Notified Coinmint Of Their Non-Renewal Of Colocation Mining Services Agreement Dated July 1, 2021

Offerings

PHUN

Phunware Enters Amended And Restated Equity Distribution Agreement; May Offer & Sell Shares For Aggregate Gross Proceeds Up To $171.5M From Time To Time

AIXI

Xiao-I Entered Into Private Placement & Securities Purchase Agreement To Issue, Sell Convertible Promissory Note For $2.1M

LIVN

LivaNova Says CMS Maintains VNS Therapy For DRE At Level 5 APC Under 2025 Medicare Hospital Outpatient Prospective Payment System; Co Will Continue To Pursue Reimbursement Opportunities For VNS Therapy For DRE

Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares traded higher Friday as striking employees are expected to vote on a new contract proposal on Monday, Nov. 4. Here&#8217;s<a href="https://www.benzinga.com/markets/equities/24/11/41676667/boeing-sweetens-deal-with-38-wage-hike-12k-bonus-and-more-to-end-7-week-strike-vote-set-for-mond"> what you need to know.</a>
What To Know: According to<a href="https://aviationweek.com/aerospace/manufacturing-supply-chain/boeing-machinists-reach-new-tentative-deal#:~:text=The%20new%20proposed%20deal%2C%20reached,Boeing%20and%20the%20union%20show."> Aviation Daily</a>, the company announced a tentative deal with the International Association of Machinists (IAM), potentially ending a 49-day strike. This union-recommended agreement proposes a 38% wage increase over four years—13% in the first year, followed by 9% in each of the next two years and 7% in the final year. 
Additionally, workers would receive a $12,000 ratification bonus and improved 401(k) contributions. Boeing also committed to locating any new aircraft production in the Puget Sound region of Washington, a key concession for the union.
This deal comes after union members previously rejected two offers, including a 35% wage increase in October. The initial union request included a 40% wage increase and pension restorations, but the new deal focuses on wage hikes and bonuses, while pensions remain unchanged. If approved, Boeing expects production facilities to gradually reopen as early as Nov. 6, with full staffing anticipated over the following weeks.
The strike and production delays have impacted Boeing's suppliers, with some, like Spirit AeroSystems, already implementing employee furloughs. Boeing CEO Kelly Ortberg emphasized the importance of a careful restart process, citing ongoing issues with production stability and meeting FAA safety standards.
What Else: Boeing&#8217;s rating also remains on S&amp;P&#8217;s CreditWatch following a larger-than-anticipated equity issuance, which helps offset projected cash flow deficits through 2025. However, S&amp;P noted Boeing's limited flexibility for further cash flow pressures and cited ongoing strike-related and post-strike operational risks as areas of concern.
BA Price Action: Boeing shares were up 3.5% at $154.59 on Friday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="539" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01152847/BA-1024x539.png" alt="" class="wp-image-626219" style="width:451px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01152847/BA-1024x539.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01152847/BA-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01152847/BA-768x405.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/01152847/BA.png 1441w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/24/11/41693751/biden-can-blame-boeing-for-massive-jobs-data-miss">Biden Can Blame Boeing For Massive Jobs Data Miss</a></li>
</ul>
Photo via Shutterstock.

Movers

Why Boeing Shares Traded Higher On Friday

WIIM

Sherwin-Williams shares are trading higher after it was announced that the company will join the Dow Jones Industrial Average.

NVDA

NVIDIA shares are trading higher after it was announced that the company will join the Dow Jones Industrial Average.

RDZN

Roadzen Files For Mixed Shelf Of Up To $100M

Purple Biotech (PPBT) has released an update. Purple Biotech, a NASDAQ/TASE-listed company, is poised to deliver multiple clinical data readouts in...

Purple Biotech Targets Key Oncology Milestones

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Purple Biotech (PPBT – Research Report) and Aligos T...

Analysts Offer Insights on Healthcare Companies: Purple Biotech (PPBT) and Aligos Therapeutics (ALGS)

Purple Biotech (PPBT) has released an update. Purple Biotech Ltd. has announced a change in the ratio of its American Depositary Shares (ADSs) to r...

Purple Biotech Announces ADS Ratio Change

These are the upcoming stock splits for the week of September 16 to September 20, based on&nbsp;TipRanks' Stock Splits Calendar. A stock split is a...

Upcoming Stock Splits This Week (September 16 to September 20) – Stay Invested

Purple Biotech (PPBT) has released an update. Purple Biotech has presented promising interim data from a Phase 2 study, suggesting that their lead ...

Purple Biotech Reveals Optimistic Cancer Treatment Data

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Purple Biotech (PPBT – Research Report). The associated price target wa...

Buy Rating Justified by Promising CM24 Phase 2 Study for Pancreatic Cancer Survival

Purple Biotech (PPBT) has released an update. Purple Biotech Ltd. has successfully met the minimum bid price requirement for continued listing on t...

Purple Biotech Regains Nasdaq Compliance

Purple Biotech (PPBT) has released an update. Purple Biotech, a company listed on NASDAQ/TASE under the symbol PPBT, has reinforced its financial p...

Purple Biotech Anticipates Key Clinical Milestones

Purple Biotech (PPBT) has released an update. Purple Biotech Ltd., a clinical-stage bio-pharmaceutical company, is set to present its groundbreakin...

Purple Biotech Unveils CAPTN-3 Cancer Therapy

Purple Biotech (PPBT) announced new data regarding its tri-specific antibody platform, CAPTN-3, which were presented at the 36th European Organizat...

Purple Biotech presents data for tri-specific antibody platform CAPTN-3

ALGS

DECK

ISPC

KSCP

PPBT

ZEPP

Press Releases

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Health Care

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Earnings

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Comments

Purple Biotech

Noticias

Últimas noticias sobre Purple Biotech (NASDAQ:PPBT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL